Press "Enter" to skip to content

Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11

  • Health Canada has approved Sanofi’s SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) DUPIXENT (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • DUPIXENT is also approved in Canada to treat adult patients with severe chronic rhinosinusitis with nasal polyposis and for the treatment of severe asthma in patients 12 years and older.
  • Also, both companies announced FDA approval of immunotherapy Libtayo (cemiplimab-rwlc) as monotherapy in newly diagnosed advanced lung cancer.
  • Price Action: SNY is up 0.2% at $46.47, while REGN is down 2.3% at $449.8 in market trading hours on last check Tuesday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *